Baseline characteristics and outcome measures after natural dendritic cell vaccination
| pDC-MEL1 | mDC-MEL1 | mDC-PROS2 | ||
|---|---|---|---|---|
| Cancer type | Melanoma | Melanoma | Prostate | |
| Patients | Male/female | 10/5 | 10/4 | 12/0 |
| Age, years | Median (range) | 52 (35–69) | 50 (31–73) | 69.5 (52–78) |
| Disease stage | M1a | 1 | 4a | 2 |
| M1b | 8 | 2 | 5 | |
| M1c | 6 | 9 | 3 | |
| Unknown | 0 | 0 | 2 | |
| Line of systemic treatment | 1st line | 14 | 14 | 0 |
| 2nd line or later | 1 | 0 | 12b | |
| Number of vaccines received | 2 or 3 | 12 | 9 | 12 |
| 6 | 2 | 2 | – | |
| 9 | 1 | 3 | – | |
| Vaccine-specific toxicity | Grade 1 | 6 | 4 | n.a. |
| Grade 2 | 0 | 1 | n.a. | |
| Immunological responses | Control antigenc (blood) | T-cell: 10/14Ab: 12/15 | T-cell. 11/13Ab: 4/13 | T-cell: n.t.Ab: 4/12 |
| Control antigen (DTH) | n.t. | n.t. | 4/12d | |
| Tumor antigen (blood) | 7/15e | 4/12 | 0/12 | |
| Tumor antigen (DTH) | 2/15 | 4/13 | 0/12d | |
| Progression-free survival | Median (range; months) | 4.0 (< 4–20) | 2.8 (< 4–67+) | n.a. |
| Overall survival | Median (range; months) | 22.3 (< 4–64) | 13.3 (< 4–67+) | 18 (6–40+) |
aIncluding 1 irresectable stage III melanoma patient
bAll patients received 2–4 lines of hormonal treatment. Four patients received prior chemotherapy
cT-cell proliferation upon stimulation with the control antigen (T-cell) and control antigen-specific antibodies (Ab) are shown
dSkin reaction tested only
eNo tumor-specific T-cells were detected prior to restimulation
Abbreviations: n.a., not available; n.t., not tested